Literature DB >> 11297701

A reevaluation of the duration of survival after the onset of dementia.

C Wolfson1, D B Wolfson, M Asgharian, C E M'Lan, T Ostbye, K Rockwood, D B Hogan.   

Abstract

BACKGROUND: Dementia shortens life expectancy; estimates of median survival after the onset of dementia have ranged from 5 to 9.3 years. Previous studies of people with existing dementia, however, may have underestimated the deleterious effects of dementia on survival by failing to consider persons with rapidly progressive illness who died before they could be included in a study (referred to as length bias).
METHODS: We used data from the Canadian Study of Health and Aging to estimate survival from the onset of symptoms of dementia; the estimate was adjusted for length bias. A random sample of 10,263 subjects 65 years old or older from throughout Canada was screened for cognitive impairment. For those with dementia, we ascertained the date of onset and conducted follow-up for five years.
RESULTS: We analyzed data on 821 subjects, of whom 396 had probable Alzheimer's disease, 252 had possible Alzheimer's disease, and 173 had vascular dementia. For the group as a whole, the unadjusted median survival was 6.6 years (95 percent confidence interval, 6.2 to 7.1). After adjustment for length bias, the estimated median survival was 3.3 years (95 percent confidence interval, 2.7 to 4.0). The median survival was 3.1 years for subjects with probable Alzheimer's disease, 3.5 years for subjects with possible Alzheimer's disease, and 3.3 years for subjects with vascular dementia.
CONCLUSIONS: Median survival after the onset of dementia is much shorter than has previously been estimated.

Entities:  

Mesh:

Year:  2001        PMID: 11297701     DOI: 10.1056/NEJM200104123441501

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  122 in total

1.  Vascular cognitive impairment.

Authors:  Laura Pedelty; David L Nyenhuis
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-05

Review 2.  [Comorbidity oriented oncology - an overview].

Authors:  Ralph Simanek; Michael Wuensch; Roland Edlinger; Bernhard Hammerl-Ferrari; Ludwig Kramer; Klaus Geissler
Journal:  Wien Klin Wochenschr       Date:  2010-04       Impact factor: 1.704

3.  Health Insurance Dynamics: Methodological Considerations and a Comparison of Estimates from Two Surveys.

Authors:  John A Graves; Pranita Mishra
Journal:  Health Serv Res       Date:  2016-02-03       Impact factor: 3.402

4.  Nonparametric tests for right-censored data with biased sampling.

Authors:  Jing Ning; Jing Qin; Yu Shen
Journal:  J R Stat Soc Series B Stat Methodol       Date:  2010-11-01       Impact factor: 4.488

5.  [Diagnostic value of multislice perfusion CT in dementia patients].

Authors:  F Streitparth; G Wieners; A Kämena; R J Schröder; H Stiepani; T Kokocinski; R Röttgen; E Steinhagen-Thiessen; R Lenzen-Grossimlimghaus; N Hidajat
Journal:  Radiologe       Date:  2008-02       Impact factor: 0.635

6.  A formal test for the stationarity of the incidence rate using data from a prevalent cohort study with follow-up.

Authors:  Vittorio Addona; David B Wolfson
Journal:  Lifetime Data Anal       Date:  2006-08-18       Impact factor: 1.588

7.  Score Estimating Equations from Embedded Likelihood Functions under Accelerated Failure Time Model.

Authors:  Jing Ning; Jing Qin; Yu Shen
Journal:  J Am Stat Assoc       Date:  2014-10       Impact factor: 5.033

Review 8.  Neuropsychological differences between frontotemporal dementia and Alzheimer's disease: a review.

Authors:  Michal Harciarek; Krzysztof Jodzio
Journal:  Neuropsychol Rev       Date:  2005-09       Impact factor: 7.444

Review 9.  Barriers to excellent end-of-life care for patients with dementia.

Authors:  Greg A Sachs; Joseph W Shega; Deon Cox-Hayley
Journal:  J Gen Intern Med       Date:  2004-10       Impact factor: 5.128

10.  Causes of syncope in patients with Alzheimer's disease treated with donepezil.

Authors:  Philippe Bordier; Stephane Lanusse; Stephane Garrigue; Charlotte Reynard; Frederic Robert; Laurent Gencel; Alexia Lafitte
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.